The prevalence of RAS/RAF/MEK/ERK pathway mutation in AS varies across studies, ranging from no mutation (78, 81) to mutation frequencies as high as 53% (27), depending on the anatomic tumor location (Supplementary 2). Here, MAP2K7 is linked to neoplasm.